Myasthenia Gravis: An Acquired Interferonopathy? - Sorbonne Université Access content directly
Journal Articles Cells Year : 2022

Myasthenia Gravis: An Acquired Interferonopathy?

Abstract

Myasthenia gravis (MG) is a rare autoimmune disease mediated by antibodies against components of the neuromuscular junction, particularly the acetylcholine receptor (AChR). The thymus plays a primary role in AChR-MG patients. In early-onset AChR-MG and thymoma-associated MG, an interferon type I (IFN-I) signature is clearly detected in the thymus. The origin of this chronic IFN-I expression in the thymus is not yet defined. IFN-I subtypes are normally produced in response to viral infection. However, genetic diseases called interferonopathies are associated with an aberrant chronic production of IFN-I defined as sterile inflammation. Some systemic autoimmune diseases also share common features with interferonopathies. This review aims to analyze the pathogenic role of IFN-I in these diseases as compared to AChR-MG in order to determine if AChR-MG could be an acquired interferonopathy.
Fichier principal
Vignette du fichier
67-Payet et al. Cells 2022.pdf (1.12 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-03641038 , version 1 (17-11-2023)

Identifiers

Cite

Cloé Payet, Axel You, Odessa-Maud Fayet, Nadine Dragin, Sonia Berrih-Aknin, et al.. Myasthenia Gravis: An Acquired Interferonopathy?. Cells, 2022, 11 (7), pp.1218. ⟨10.3390/cells11071218⟩. ⟨hal-03641038⟩
48 View
4 Download

Altmetric

Share

Gmail Facebook X LinkedIn More